NR546-FINALEXAM-PEARLS QUESTIONS
AND ANSWERS 100% CORRECT!!
First line treatment for depression - ANSWER SSRIs
Common side effect of SSRIs - ANSWER sexual dysfunction
rapid cycling bipolar disorder - ANSWER Minimum of 4 episodes a year
Goal of antidepressant therapy - ANSWER complete remission of symptoms
Serotonin GI effects - ANSWER Due to the fact that 90% of 5HT receptors are located
in GI tract
best tolerated SSRI - ANSWER Escitalopram (Lexapro) also has fewest CYP
interactions
Lithium levels - ANSWER Can be increased by NSAIDS and ACE inhibitors
Can be decreased by caffeine and mania
Unaffected by amiloride, furosemide, and sulindac
Lithium purpose - ANSWER Effective treatment for manic episodes, to prevent
reoccurrence and to a lower degree is effective in depressive episodes
Lamotrigine - ANSWER Well tolerated except for the propensity to cause a rash
Monoamines - ANSWER dopamine, norepinephrine, serotonin
Lamotrigine - ANSWER Is a mood stabilizer
Lithium - ANSWER Well established to prevent suicide in clients with mood disorders
Lithium - ANSWER Has a narrow therapeutic window and requires law draws
1st line treatment for OCD - ANSWER SSRIs are first line. Benzodiazepines are not!!!
, Primary action of hallucinogenic drugs such as LSD,mescaline, psilocybin, and MDMA -
ANSWER Agonism of 5HT2A receptors
Hallucinogens may have additional actions at other serotonin receptors (particularly
5HT1A and 5HT2C) and at other neurotransmitter systems, and MDMA in particular
also blocks the serotonin transporter (SERT)
Controls appetite - ANSWER hypothalamus serves as the brain center that controls
appetite by utilizing a complex set of circuits and regulators. One formulation of how the
hypothalamus does this is the notion that there is a major appetite stimulating pathway
whose actions are mediated by two peptides (neuropeptide Y and agouti-related
protein)
Phentermine - ANSWER Acts like amphetamine, blocking both the dopamine
transporter (DAT) and the norepinephrine transporter (NET) and, at high doses, the
vesicular monoamine transporter (VMAT)
Buprenorphine - ANSWER Is also approved for <18 year olds
Disulfiram - ANSWER Irreversibly inhibits aldehyde dehydrogenase resulting in build of
toxic levels of acetaldehyde
Acamprosate reduces glutamate release associated with alcohol withdrawal, naltrexone
blocks the enjoyment of heavy drinking through its action on reward circuitry.
sedative-hypnotics - ANSWER Act at GABA A receptor sites in reward circuits
Impulsive Disorders - ANSWER Focused on reward and associated with Mesolimbic
pathway
The Tuberomammillary nucleus (TMN) - ANSWER contains the on switch where as the
off switch is located in the ventrolateral preoptic nucleus (VLPO)
Guanfacine - ANSWER Is an alpha 2 agonist
Methylphenidate - ANSWER Is a dopamine norepinephrine multimodal
Amphatamines - ANSWER Is a dopamine norepinephrine reuptake inhibitor (DN-RIRe),
stimulant
Welbutrin (bupropion) - ANSWER Antidepressant NDRI
Hyperactivity is modulated by - ANSWER The prefrontal cortec
AND ANSWERS 100% CORRECT!!
First line treatment for depression - ANSWER SSRIs
Common side effect of SSRIs - ANSWER sexual dysfunction
rapid cycling bipolar disorder - ANSWER Minimum of 4 episodes a year
Goal of antidepressant therapy - ANSWER complete remission of symptoms
Serotonin GI effects - ANSWER Due to the fact that 90% of 5HT receptors are located
in GI tract
best tolerated SSRI - ANSWER Escitalopram (Lexapro) also has fewest CYP
interactions
Lithium levels - ANSWER Can be increased by NSAIDS and ACE inhibitors
Can be decreased by caffeine and mania
Unaffected by amiloride, furosemide, and sulindac
Lithium purpose - ANSWER Effective treatment for manic episodes, to prevent
reoccurrence and to a lower degree is effective in depressive episodes
Lamotrigine - ANSWER Well tolerated except for the propensity to cause a rash
Monoamines - ANSWER dopamine, norepinephrine, serotonin
Lamotrigine - ANSWER Is a mood stabilizer
Lithium - ANSWER Well established to prevent suicide in clients with mood disorders
Lithium - ANSWER Has a narrow therapeutic window and requires law draws
1st line treatment for OCD - ANSWER SSRIs are first line. Benzodiazepines are not!!!
, Primary action of hallucinogenic drugs such as LSD,mescaline, psilocybin, and MDMA -
ANSWER Agonism of 5HT2A receptors
Hallucinogens may have additional actions at other serotonin receptors (particularly
5HT1A and 5HT2C) and at other neurotransmitter systems, and MDMA in particular
also blocks the serotonin transporter (SERT)
Controls appetite - ANSWER hypothalamus serves as the brain center that controls
appetite by utilizing a complex set of circuits and regulators. One formulation of how the
hypothalamus does this is the notion that there is a major appetite stimulating pathway
whose actions are mediated by two peptides (neuropeptide Y and agouti-related
protein)
Phentermine - ANSWER Acts like amphetamine, blocking both the dopamine
transporter (DAT) and the norepinephrine transporter (NET) and, at high doses, the
vesicular monoamine transporter (VMAT)
Buprenorphine - ANSWER Is also approved for <18 year olds
Disulfiram - ANSWER Irreversibly inhibits aldehyde dehydrogenase resulting in build of
toxic levels of acetaldehyde
Acamprosate reduces glutamate release associated with alcohol withdrawal, naltrexone
blocks the enjoyment of heavy drinking through its action on reward circuitry.
sedative-hypnotics - ANSWER Act at GABA A receptor sites in reward circuits
Impulsive Disorders - ANSWER Focused on reward and associated with Mesolimbic
pathway
The Tuberomammillary nucleus (TMN) - ANSWER contains the on switch where as the
off switch is located in the ventrolateral preoptic nucleus (VLPO)
Guanfacine - ANSWER Is an alpha 2 agonist
Methylphenidate - ANSWER Is a dopamine norepinephrine multimodal
Amphatamines - ANSWER Is a dopamine norepinephrine reuptake inhibitor (DN-RIRe),
stimulant
Welbutrin (bupropion) - ANSWER Antidepressant NDRI
Hyperactivity is modulated by - ANSWER The prefrontal cortec
